<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621356</url>
  </required_header>
  <id_info>
    <org_study_id>2021-1924</org_study_id>
    <secondary_id>NL78278.091.21</secondary_id>
    <nct_id>NCT05621356</nct_id>
  </id_info>
  <brief_title>Monitoring Allergen Immunotherapy in Allergic Rhinitis</brief_title>
  <official_title>Monitoring Allergen Immunotherapy in Allergic Rhinitis; is Nasal Fluid the Way to Precision Medicine?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis (hay fever) can be treated successfully with allergen-specific&#xD;
      immunotherapy (AIT) for 3-5 years. This relative expensive and prolonged treatment is not&#xD;
      suitable for everyone and therefore it is important to predict who will benefit from this&#xD;
      therapy early after the start of treatment.&#xD;
&#xD;
      This project will investigate whether a BAT with nasal fluid can detect inhibition during&#xD;
      immunotherapy in comparison with a BAT with blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic rhinitis (hay fever) can be treated successfully with allergen-specific&#xD;
      immunotherapy (AIT) for 3-5 years. This relative expensive and prolonged treatment is not&#xD;
      suitable for everyone and therefore it is important to predict who will benefit from this&#xD;
      therapy early after the start of treatment. Biomarkers, like Basophil Activation Test (BAT)&#xD;
      and IgE-facilitated allergen binding (FAB), using nasal fluid instead of blood, probably&#xD;
      better reflect therapy effect (inhibition of an IgE-mediated allergic reaction) as the nose&#xD;
      is the main target organ for AIT in allergic rhinitis.&#xD;
&#xD;
      This project will investigate whether a BAT with nasal fluid can detect inhibition during&#xD;
      immunotherapy in comparison with a BAT with blood. Nasal fluid and blood samples are&#xD;
      collected at baseline and after 8 and 16 weeks of treatment. A nasal fluid inhibition BAT is&#xD;
      developed and validated by comparison with a BAT using serum and an IgE-FAB assay.&#xD;
&#xD;
      15 adults with birch pollen allergy, who are treated with AIT (Itulazax birch pollen tablet)&#xD;
      and 10 adults with birch pollen allergy, who are treated with immunosuppressive medication&#xD;
      (control group) will be included in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2022</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BAT outcome nasal fluid</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BAT outcome nasal fluid</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BAT outcome serum</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BAT outcome serum</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG4/IgA-associated inhibitory activity in nasal fluid</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG4/IgA-associated inhibitory activity in nasal fluid</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG4/IgA-associated inhibitory activity in serum</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG4/IgA-associated inhibitory activity in serum</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Immunotherapy</condition>
  <condition>Rhinitis, Allergic</condition>
  <condition>Treatment Outcome</condition>
  <arm_group>
    <arm_group_label>allergen-specific immunotherapy (AIT)</arm_group_label>
    <description>Adults with birch pollen allergy, who are treated with allergen-specific immunotherapy (AIT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>Adults with birch pollen allergy, who are treated with immunosuppressive medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>A nasal fluid Basophil Activation Test (BAT)</intervention_name>
    <description>a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.</description>
    <arm_group_label>allergen-specific immunotherapy (AIT)</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Birch pollen allergic patients who are treated with Itulazax (birch pollen SLIT-tablet) and&#xD;
        birch pollen allergic patients who are treated with immunosuppressive medication (control&#xD;
        group).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IgE-sensitized birch pollen allergy&#xD;
&#xD;
          -  Start of Itulazax therapy or immunosuppressive therapy (nasal corticosteroid and/or&#xD;
             antihistamine eye drops)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other underlying chronic conditions (immunological (autoimmune or immunodeficiency),&#xD;
             oncological)&#xD;
&#xD;
          -  Unstable uncontrolled asthma&#xD;
&#xD;
          -  Smoking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janneke Ruinemans-Koerts</last_name>
    <phone>0031 88 005 8888</phone>
    <email>j.ruinemans-koerts@rijnstate.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janneke Ruinemans-Koerts</last_name>
      <phone>0031 88 005 8888</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

